Losortan Potassium Tablet, Film Coated
Product Images NDC 50268-505

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losortan Potassium (NDC 50268-505). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

25mg (504 15 25mg)

Losartan Potassium Tablets USP 25 mg film-coated tablets label from AvPAK. The label shows a package containing 50 tablets in unit dose format (5 x 10). It includes storage instructions to keep the product between 20° to 25°C and out of reach of children. The label features the AvPAK logo and specifies it is for prescription use only.*

FDA Label Image

50mg (505 15 50mg)

Losartan Potassium Tablets USP 50 mg film-coated tablets label showing dosage strength and quantity of 50 tablets (5 x 10 unit dose). The label includes the NDC 50268-505-15, Rx Only designation, storage instructions, and manufacturer information as AvPAK, a product of AvKARE, located in Pulaski, Tennessee.*

FDA Label Image

100mg (506 15 100mg)

Losartan Potassium Tablets USP 100 mg film-coated tablets label showing a pack size of 50 tablets (5 x 10) unit dose. The label is marked Rx only and includes storage instructions, a barcode, and manufacturer information for AvPAK, a product of AvKARE, based in Pulaski, TN.*

FDA Label Image

Losapotatab1 (C516a5a7 Cfc8 4b3b A8bc 7644c3313673 01)

Chemical structure of Losartan Potassium, showing its molecular formula representation with key atoms and bonds, including potassium ion (K+).*

FDA Label Image

Losapotatab2 (C516a5a7 Cfc8 4b3b A8bc 7644c3313673 02)

A line graph comparing the percentage of patients with a primary endpoint over study months between treatments Atenolol (dashed line) and Losartan Potassium (solid line). The x-axis shows study duration up to 66 months, and the y-axis shows percentage of patients, with adjusted risk reduction noted as 13% (p=0.021).*

FDA Label Image

Losapotatab3 (C516a5a7 Cfc8 4b3b A8bc 7644c3313673 03)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over study months for Atenolol and Losartan Potassium. The x-axis represents study months from 0 to 66, and the y-axis shows the percentage of patients ranging from 0 to 8%. The graph shows lower stroke rates for Losartan Potassium compared to Atenolol, with an adjusted risk reduction of 25% noted.*

FDA Label Image

Losapotatab (C516a5a7 Cfc8 4b3b A8bc 7644c3313673 04)

A forest plot chart comparing the hazard ratios of Losartan-K versus Atenolol for primary composite events and stroke (fatal/non-fatal) across various patient subgroups. The chart shows event rates, hazard ratios, and confidence intervals stratified by age, gender, race, ischemic heart disease status, diabetes, and cardiovascular disease history. The horizontal axis indicates favorability towards Losartan-K or Atenolol.*

FDA Label Image

Losapotatab5 (C516a5a7 Cfc8 4b3b A8bc 7644c3313673 05)

A line graph comparing the percentage of patients with events over a 48-month period between Losartan Potassium Tablet and placebo groups. The graph shows a risk reduction of 16.1% with a p-value of 0.022, indicating statistical significance.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.